ACMI - Accumed Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Frank Buck who wrote (628)	12/10/1997 12:28:00 AM
From: Cisco	Read Replies (2) of 1894

Frank, Did you get a chance to listen to ACMI's Shareholder Conference Call of December 5? I just finish listening to the recorded playback. I walked away very encouraged with the future of the company. It is only a matter of time! For those who are interested, you can listen to the playback by calling (706) 645-9291 and using the PIN # 761820. Also for the record, AccuMed filed a 10-QSB/A, a 8-K/A, and a S-3/A today. I have been digging through them and really didn't see any big news. The 10-QSB/A showed a few minor changes on the Consolidated Balance Sheet but the Consolidated Statement of Operations showed no changes. The Management's Discussion and Analysis of Financial Condition and Results of Operations include a few additional explanatory paragraphs. The majority of the increased sales during the last nine months has been the microbiology product line. Here is a link to the updated Management's Discussion and Analysis: edgar-online.com The 8-K/A had no significant changes. The S-3/A was amended to incorporate the new 8-K/A and 10-QSB/A by reference. From the conference call it appears that 1998 is going to be a very good year for the cytopathology sales both in the US and overseas. Interest in their product appears to growing rapidly now. Contracts are being signed. The Boston show appears to have paid off well and they have more road shows scheduled for the first quarter. They plan to seek FDA approval for an updated system during the 1st quarter of 98. If I was listening correctly, I heard the CEO say the system even works better with monolayer preps than with conventional smears. The future may be ThinPrep read by TracCell! Peter said to expect some fall out from the various players within the cytopathology area. Also, thanks Mystery Man for requesting better investor relations! Cisco

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next